Mutations in FLT3 gene are one of the most common mutations detected in acute myeloid leukemia (AML). The presence of these mutations has adverse prognostic significance for patients with AML. Detection of these mutations is used not only as a factor of prognosis, but also as a marker for monitoring minimal residual disease.
The detection of two major mutations in the FLT3 gene is carried out at the Laboratory for Molecular Biomedicine. We perform the detection of internal tandem duplication of the juxta- membrane domain (ITD) and the point mutation in the codon 835 of the kinase domain (D835). For the detection of FLT3-ITD mutations we use PCR method, while for the detection of FLT3-D835 mutation we use PCR-RFLP method.
It is necessary to deliver 4 to 5 ml of bone marrow or peripheral blood (depending on the disease phase) using 3.8% sodium citrate as anticoagulant in vol/vol ratio 9:1. The sample is required to be delivered fresh, without freezing, during the same day. The samples are accepted every day from 10 to 13h. It is possible to deliver the sample via post express service. The analysis is performed within 10 working days. The results and the bill are sent to the patient's home address, or can be collected personally at the Institute from 10 to 16h every day.
For payment instructions, please contact us.
- Irena Marjanović
- dr Nataša Tošić
- dr Sonja Pavlović
Tel: +381 11 3976 445
Mob: +381 65 3976 445
Fax: +381 11 3975 808